1656P - Myeloid-Derived Suppressor Cells are associated with a decrease of tumor antigen-specific Th1 immunity in Non-Small Cell Lung Cancer.

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Lung and other Thoracic Tumours
Translational Research
Presenter Olivier Adotevi
Citation Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390
Authors O. Adotevi1, E. Lauret Marie Joseph1, C. Laheurte1, M. Dosset1, E. Fabre-Guillevin2, P. Jacoulet3, G. Eberts3, G. Helluin1, L. Boullerot1, L. Rangan1, Y. Godet1, V. Westeel3
  • 1Thérapeutique Immuno-moléculaire Des Cancers, UMR1098, 25020 - Besançon/FR
  • 2Medical Oncology, Dr. Elizabeth Fabre-Guillevin, 75015 - La Défense/FR
  • 3Pneumology, CHRU Jean Minjoz, 25000 - Besançon/FR

Abstract

Background

Myeloid Derived Suppressor cells (MDSC) are immune suppressive cells associated with poor survival in several cancers. In this study, we investigated their impact on spontaneous tumor antigen specific Th1 responses in Non-Small Cell Lung Cancer (NSCLC).

Methods

Monocytic MDSC (M-MDSC) (Lin-HL-DR-/loCD11b+CD14+CD33+) were measured in peripheral blood of 122 NSCLC patients and 34 healthy donors by flow cytometry. The presence of spontaneous anti-tumor Th1 response was measured by IFN-ɣ ELISPOT assay using mixture of peptides derived from lung cancer-associated tumor antigens such as telomerase, NY-ESO1 and Wilms Tumor-1. Patients’ samples were collected at baseline before any treatment.

Results

Higher percentage of circulating M-MDSC was found in NSCLC patients compared to healthy subjects (mean: 3.9±0.4% vs 1.5±0.4%, p 

Conclusions

Our results show that high levels of circulating M-MDSC is associated with a decrease of pre-existing antitumor T cell response. The level of M-MDSC combined with antitumor T cell responses could predict distinct clinical outcome. Thus, monitoring M-MDSC in blood could be used as relevant immune biomarker in NSCLC.

Clinical trial identification

Legal entity responsible for the study

Adotevi Olivier

Funding

None

Disclosure

All authors have declared no conflicts of interest.